HIV / AIDS

The US Food and Drug Administration (FDA) has approved once-daily oral Truvada to reduce the risk of sexually acquired HIV-1 in at-risk adolescents, in combination with safe-sex practices.

Brain damage caused by HIV can begin soon after infection, according to new research, but initiating antiretroviral therapy drugs can halt the damage.

In case you missed them, we've compiled the top 5 articles from this past week.

An ambitious new trial aims to confirm that people living with HIV can be kidney donors to HIV recipients, shortening the time those recipients wait for a transplant.

Big advances in treatment can’t make up for an inability to stop new infections, which number 5,000 per day worldwide.

A new report by Global Health Technologies Coalition assesses the economic impact of cuts to global health R&D on the economies of US states.

Joseph Eron, MD, explains how integrase inhibitors have dramatically changed HIV therapy for the better.

The World Health Organization has a new way to identify cost-effective measures to address the increasing prevalence of drug-resistant HIV in sub-Saharan Africa.

Colleen Kelley, MD, describes the role of health care providers in linking patients with PrEP.

The US Food and Drug Administration (FDA) approved this new intravenously-administered HIV medication for patients who are suffering from multidrug-resistant HIV who have failed other antiretroviral therapies.

A recent study finds no difference in risk for adverse birth outcomes between 3 antiretroviral regimens taken by pregnant women with HIV, including TDF-FTC-LPV/r, a regimen that has raised safety concerns in a past trial.

Data from the Behavioral Risk Factor Surveillance System indicate two-thirds of transgender men and women have not been tested for HIV/AIDS.

Women living with HIV are at elevated risk for comorbidities as their life expectancy increases.

Infections associated with the ongoing opioid epidemic in the United States apparently know no bounds.

Unique considerations are called for when caring for intravenous drug users with newly diagnosed HIV/HCV coinfections.

Study results confirm both drug regimens are solid choices for many patients with HIV.

Joseph Eron, MD, discusses benefits of long-acting injectable antiretroviral therapy as well as misconceptions.

On National Youth HIV/AIDS Awareness Day we take a closer look at how the HIV/AIDS epidemic impacts younger individuals and what can be done to cut back on new diagnoses.

Results from a Johns Hopkins study conducted at Frere Hospital in South Africa indicate that emergency departments play a critical role in promoting HIV testing.

The risk comes after it was found that surgical instruments used for orthopedic and spine surgeries were not cleaned properly and consequently, the sterilization of those instruments was compromised.

Novel HIV drug doravirine shows good potential in a recent clinical trial comparing it with established therapy darunavir.

Dr. Tomlinson previously served as the principal deputy director for the DGHT and became the Acting Director in October 2017.

On the heels of revealing a new feature promoting HIV testing, a data analysis finds that the app was sharing sensitive information with other companies.

Only about 1 in 7 HIV-positive individuals are aware of their status.

In case you missed them, we've compiled the top 5 articles from this past week.

Joseph Eron, MD, explains how some individuals acquire resistance to HIV therapy and discusses new drugs in the pipeline that are effective against resistant virus.

This comes on the heels of 2 recent FDA approvals of 2 Mylan antiretrovirals: Cimduo and Symfi Lo.

Colleen Kelley, MD, stresses the importance of routinizing HIV testing and shares what physicians can do if their patient declines the option to get tested.

A recent study finds that daily antituberculosis therapy is more effective than a thrice-weekly regimen among HIV-positive patients with pulmonary tuberculosis.

A new study finds that a 1-month course of antibiotics is as safe & effective as the commonly recommended 9-month course in preventing tuberculosis in those with HIV.